NEWS
Morphocell Technologies appoints Marc Courtois to Board of Directors
Montreal, QC, June 19, 2024 – Morphocell Technologies is pleased to announce the appointment of Marc Courtois as a member of its Board of Directors, effective immediately.
Mr. Courtois brings over 20 years of extensive experience as an investment banker with RBC Capital Markets, where he managed the coverage of the firm’s largest clients in Quebec, including Quebecor, BCE, and Air Canada. He played a pivotal role in significant transactions such as the IPOs of Air Canada, Bell Canada International, and Quebecor World, as well as the joint acquisition of control of Continental Airlines by Air Canada and TPG Capital. His expertise also extends to the sale of Montreal Trust by BCE, the sale of control of Donohue by Quebecor, and the acquisitions of World Color and Videotron by Quebecor.
Following his successful banking career, Mr. Courtois has been actively involved in board work. He is a past chairman of Canada Post, NAV Canada, Aireon, and the Pembroke American Growth Fund, and a former director of Groupe TVA and Ovivo. Additionally, he has contributed significantly to the community as the past chairman of the Montreal Children’s Foundation and a former director of the MUHC and the MUHC Foundation. Mr. Courtois holds an MBA from the Ivey Business School and a BA from Concordia.
Massimiliano Paganelli, CEO of Morphocell Technologies, expressed his enthusiasm about Mr. Courtois’s appointment, stating, “Marc’s remarkable background and his strategic insight will be invaluable to Morphocell. His experience in guiding major corporations through complex transactions and his dedication to board governance align perfectly with our vision for growth and innovation.”
This key appointment demonstrates Morphocell Technologies' commitment to robust governance and strategic refinement. Mr. Courtois’s knowledge will support Morphocell in its growth to become a leading entity in the life sciences and biotechnology sectors in Quebec and Canada.
About Morphocell Technologies:
Morphocell Technologies Inc. is a Laval (QC)-based regenerative medicine company focused on the development and commercialization of stem cell-derived tissue and organ replacement therapies. Its iPSC-derived platform technology has a large pipeline potential touching different organ deficiencies, with severe liver disease being the initial focus. Morphocell prides itself on its culture of innovation, technical excellence, and commitment to improving patients' lives.
Media Contact:
Zaynah Ibrahim
+ 1 (514) 373-6444 ext. 106